A Study on the Efficacy of Atezolizumab Combined with Chemotherapy

Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Study ID
NCT06780826
Status
Recruiting
Apply to this trial

Conditions

  • Lung Cancer, Small Cell

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab — DRUG
    Atezolizumab, 1200 mg intravenous infusion, 21 days per cycle
  • Etoposide — DRUG
    Etoposide,intravenous infusion, 100mg/m,21 days per cycle
  • Carboplatin — DRUG
    carboplatin,intravenous infusion, AUC=5, 21 days per cycle.

Study Details

This is a multicenter phase III simulated RCT study aimed to compare the efficacy and safety of atezolizumab combined with chemotherapy versus placebo combined with chemotherapy in small cell lung cancer.

Key Dates

Start date
Aug 28, 2024
Status verified
Jan 2025
Primary completion
Jun 30, 2025
Completion
Sep 30, 2025

Study Design

Enrollment
1,430 participants (estimated)

Arms

  • Arm: atezolizumab combined with chemotherapy
    Patients receive atezolizumab in combination with carboplatin and etoposide
  • Arm: chemotherapy
    Patients received carboplatin and etoposide

Primary Outcome Measure

progression free survival [ Time Frame: 12 months ]

Central Contacts

Related Studies